A carregar...

Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data

Background: Double blockade with pertuzumab and trastuzumab combined with chemotherapy is the standard neoadjuvant treatment for HER2-positive early breast cancer. Data derived from clinical trials indicates that the response rates differ among intrinsic subtypes of breast cancer. The aim of this st...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Oncol
Main Authors: Díaz-Redondo, Tamara, Lavado-Valenzuela, Rocio, Jimenez, Begoña, Pascual, Tomas, Gálvez, Fernando, Falcón, Alejandro, Alamo, Maria del Carmen, Morales, Cristina, Amerigo, Marta, Pascual, Javier, Sanchez-Muñoz, Alfonso, González-Guerrero, Macarena, Vicioso, Luis, Laborda, Aurora, Ortega, Maria Victoria, Perez, Lidia, Fernandez-Martinez, Aranzazu, Chic, Nuria, Jerez, Jose Manuel, Alvarez, Martina, Prat, Aleix, Ribelles, Nuria, Alba, Emilio
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2019
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6848376/
https://ncbi.nlm.nih.gov/pubmed/31750258
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2019.01178
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!